Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer in the United States. Its technology platforms comprise dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The companys product candidates include DCVax-Prostate for the treatment of non-metastatic hormone independent prostate cancer, which cleared Phase III clinical trial; DCVax-Brain that is in Phase II clinical trial for the treatment of Glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-small cell lung cancer. Its product candidates also comprise DCVax-Direct that cleared Phase I clinical trial for the treatment of ovarian, head, and neck cancer; and DCVax-L, which completed Phase I/II clinical trials for the treatment of resectable solid tumors. In addition, the company develops CXCR4 antibodies, which are involved in various phases of disease progression, including proliferation of the primary tumor, migration of cancer cells out of the primary tumor, and establishment of distant metastatic sites for the treatment of non-small cell lung, breast, colon, melanoma, prostate, pancreatic, kidney, and ovarian cancers, as well as certain blood cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Business Summary
Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer in the United States. Its technology platforms comprise dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The companys product candidates include DCVax-Prostate for the treatment of non-metastatic hormone independent prostate cancer, which cleared Phase III clinical trial; DCVax-Brain that is in Phase II clinical trial for the treatment of Glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-small cell lung cancer. Its product candidates also comprise DCVax-Direct that cleared Phase I clinical trial for the treatment of ovarian, head, and neck cancer; and DCVax-L, which completed Phase I/II clinical trials for the treatment of resectable solid tumors. In addition, the company develops CXCR4 antibodies, which are involved in various phases of disease progression, including proliferation of the primary tumor, migration of cancer cells out of the primary tumor, and establishment of distant metastatic sites for the treatment of non-small cell lung, breast, colon, melanoma, prostate, pancreatic, kidney, and ovarian cancers, as well as certain blood cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.